World's First Reported Case of Smart Insole Tech Managing Post-Traumatic Complications

Case Study Suggests Additional Neuropathic Applications for SurroSense Rx®

Calgary, AB, Canada, July 7, 2017  – Orpyx Medical Technologies Inc. announced today the medical journal Plastic Case Studies published “Use of the SurroSense Rx System for Sensory Substitution of the Insensate Plantar Foot Resurfaced With Latissimus Dorsi Muscle Free Flap and Skin Graft: A Retrospective Case Study”. This case study explores the use of Orpyx’s SurroSense Rx® system with a patient with the loss of protective sensation (LOPS) from a degloving injury of the right foot that was reconstructed with a latissimus dorsi free flap and skin graft.

The patient was fitted with the SurroSense Rx to enable ongoing plantar pressure feedback and monitored with the device over a six-month period. The device alerted the patient when dangerous time and pressure levels were exceeded on the plantar surface of the foot and provided instruction to actively take weight off the affected area.

At the end of the monitoring period, no ulcerative events occurred. According to the study, this fact was highly encouraging, suggesting that the system assisted in the secondary prevention of pressure-related injury to the affected foot. Qualitatively, the patient reported that the alerting device allowed him to think less about avoiding pressure on his right heel at all times.

The results of this study suggest that smart insoles, together with an alert-based feedback system notifying patients of harmful plantar pressures, are perceived to be effective and acceptable by high risk diabetic patients, and could enhance adherence to prescribed footwear. Specifically, this study suggests that users who receive at least one alert per two hours could enhance adherence to footwear over time, respond better to alert-based feedback, and better perceive the benefit of such a technology-based intervention.

“At Orpyx, we are inspired by stories like this, where patients’ lives are changed for the better. This case demonstrates the effectiveness of SurroSense Rx in yet another context. We look forward to helping more patients like this and helping to protect the work of reconstructive surgeons after patients are released from their care.” said Dr. Breanne Everett, CEO & co-founder of Orpyx Medical Technologies Inc.

About Orpyx Medical Technologies Inc.
Orpyx Medical Technologies Inc. (“Orpyx”) is a wearable pressure sensor technology company focused on medical applications. Orpyx’s primary intention is to address the world’s growing epidemic of diabetes and its associated complications, most notably, peripheral neuropathy, which leads to lack of circulation, numbness, or loss of protective sensation, in the feet. This problem leads to the development of foot ulcers which can ultimately lead to amputation and death infection and ulcers in the feet, also known as peripheral neuropathy. Additionally, this problem affects upwards of 60% of diabetics over the course of their disease and costs the North American health care system over $16.4 billion annually.

For more information, please contact:
Chan Mean
Marketing Manager, Orpyx Medical Technologies Inc.
chan.mean@orpyx.com
+1 403 460 0216 ext. 501




Chan Mean
Chan Mean

Author